SCHEMBL7136223

SCHEMBL7136223

COC(=O)CC(CS(=O)(=O)c1ccc(C2(c3ccc([N+](=O)[O-])cc3)SCCS2)cc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
MAPT P10636 4/20 0.39
HPGD P15428 1/20 0.39
MMP2 P08253 3/20 0.38
ALDH1A1 P00352 4/20 0.38
HSD11B1 P28845 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7078648 0.83 FNTA (0.54) KMT2AFNTAFNTBMAPTALDH1A1
SCHEMBL7078057 0.83 HSD11B1 (0.48) KMT2AFNTAFNTBMAPTHPGD
SCHEMBL7073742 0.81 KMT2A (0.45) KMT2AFNTAFNTBMAPTHPGD
SCHEMBL7079158 0.76 SMN1; SMN2 (0.43) KMT2AMAPTHPGDALDH1A1CYP2D6
SCHEMBL7073376 0.75 ALDH1A1 (0.46) KMT2AMMP2ALDH1A1HSD11B1
SCHEMBL7073310 0.75 NFE2L2 (0.49) KMT2AMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL7073308 0.75 NFE2L2 (0.49) KMT2AMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL7079124 0.74 ALDH1A1 (0.45) KMT2AFNTAFNTBMMP2ALDH1A1
SCHEMBL7079059 0.74 ALDH1A1 (0.45) KMT2AFNTAFNTBMAPTMMP2
SCHEMBL7077837 0.71 ALDH1A1 (0.45) KMT2AMMP2ALDH1A1CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003059872-A1 AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO disclosed